---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-095424"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2026-08-13T11:00:19+00:00"
generated_at: "2026-08-13T11:05:44.759891+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PTC wins bankruptcy auction for Sangamo's Fabry gene therapy ST-920; $111M upfront

## Summary
- Deal: $111M upfront plus up to $100M milestones ($80M on accelerated approval, $20M on traditional FDA approval).
- ST-920 is a one-time AAV gene therapy; BLA submission for accelerated approval expected Q4 2026.
- Phase 1/2 STAAR data showed positive eGFR slope at 52 weeks; durability up to 4.5 years in earliest patient.
- Close expected late Q3/early Q4 2026, subject to bankruptcy court approval, antitrust review, and customary conditions.
- PTC expects no impact on 2026 cash flow break-even; leverages existing rare disease commercial infrastructure.

## SEC filing metadata
- accession: 0001104659-26-095424
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2026-08-13T11:00:19+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000110465926095424/0001104659-26-095424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000110465926095424/tmb-20260812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-095424
- JSON: https://secwatch.observer/filing/0001104659-26-095424.json
- Plain text: https://secwatch.observer/filing/0001104659-26-095424.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.